Article
AstraZeneca's Evusheld loses potency against new omicron subvariant, FDA warns
Rating:
0.0
Views:
58
Likes:
1
Library:
1
For COVID-19 antibody drugs in the pandemic world, it's been life in the fast lane. | Amid reports that AstraZeneca's Evusheld is ineffective against the latest subvariant of omicron, BA.4.6, the FDA has updated its fact sheet for the antibody combo. The agency now says the product can increase the risk of COVID-19 infection for variants that it does not neutralize.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value